Table 1.
Characteristics of patients and operative findings
| Antecolic (A) group (n = 58) | Vertical retrocolic (VR) group (n = 58) | P-value | |
|---|---|---|---|
| Age (years)a | 70.0 (36–86) | 69.0 (46–86) | 0.540 |
| Gender (male/ female) | 36 (62.1%)/ 22 (37.9%) | 32 (55.2%)/ 26 (44.8%) | 0.451 |
| Body mass index (kg/m2)a | 21.8 (15.7–29.0) | 21.3 (14.7–29.3) | 0.463 |
| Pre-operative body weight (kg)a | 53.9 (35.6–78.8) | 51.9 (30.5–75.8) | 0.338 |
| Diabetes mellitus | 21 (36.2%) | 21 (36.2%) | 1.000 |
| Pre-existing on admission | 11 (19.0%) | 7 (12.1%) | 0.442 |
| Newly diagnosed | 10 (17.2%) | 14 (24.1%) | 0.359 |
| Insulin dependant | 4 (6.9%) | 5 (8.6%) | 0.729 |
| Oral administration | 9 (15.5%) | 5 (8.6%) | 0.393 |
| Pre-operative albumin (g/dl)a | 3.75 (2.94-4.78) | 3.66 (2.69-4.48) | 0.542 |
| Pre-operative total cholesterol (mg/dl)a | 177 (92–381) | 181 (115–372) | 0.204 |
| Pre-operative haemoglobin-A1c (%)a | 5.3 (3.6–11.0) | 5.2 (3.9–10.9) | 0.968 |
| Pre-operative BT-PABA test (%)a | 56.6 (10.6–82) | 53.0 (12.9–87.4) | 0.506 |
| Pre-operative biliary drainage | 38 (65.5%) | 43 (74.1%) | 0.312 |
| Length of time from presentation of disease to operation (weeks)a | 8 (3–36) | 8 (4–21) | 0.349 |
| Pathology | |||
| Benign/ malignancy | 12 (20.7%)/ 46 (79.3%) | 9 (15.5%)/ 49 (84.5%) | 0.425 |
| Pancreatic cancer | 17 (29.3%) | 16 (27.6%) | |
| Bile duct cancer | 17 (29.3%) | 20 (34.5%) | |
| Ampullary carcinoma | 4 (6.9%) | 9 (15.5%) | |
| Duodenal cancer | 2 (3.4%) | 0 | |
| Cystic tumour (IPMN, MCN) | 11 (19.0%) | 6 (10.3%) | |
| Chronic pancreatitis | 2 (3.4%) | 3 (5.2%) | |
| Benign bile duct disease | 2 (3.4%) | 2 (3.4%) | |
| Others | 3 (5.2%) | 2 (3.4%) | |
| Operative findings | |||
| Operating time (minutes)a | 558.0 (427–967) | 571.5 (422–769) | 0.712 |
| Operative blood loss (ml)a | 1380 (360–6870) | 1295 (230–3980) | 0.440 |
| Blood transfusion | 36 (62.1%) | 30 (51.7%) | 0.261 |
| Soft pancreas | 32 (55.2%) | 35 (60.3%) | 0.573 |
| Main pancreatic duct diameter (mm)a | 4 (2–10) | 3 (2–10) | 0.467 |
| Resected duodenum (cm)a | 4 (2–4) | 4 (3–4) | 0.064 |
| Portal vein resection | 8 (13.8%) | 4 (6.9%) | 0.223 |
a
Results are expressed as median (range).
BT-PABA, N-benzoyl-L-tyrosyl-para-aminobenzoic acid; IPMN, intraductal papillary mucinous neoplasm; MCN, mucinous cystic neoplasm.